

INFORMAZIONI PERSONALI Anna Lia Molinari

ESPERIENZA PROFESSIONALE

- Dal 01/12/2019 Incarico di Struttura Semplice di Unità Operativa presso UO di Ematologia, Ospedale degli Infermi Rimini-Area Vasta Romagna
- Dal 2009 al 30/11/2019 Dirigente Medico a tempo indeterminato presso UO Ematologia, Ospedale degli Infermi Rimini-Area Vasta Romagna
- Dal 1994 al 2009 Dirigente medico presso UO Ematologia, Ospedale Santa Maria delle Croci Ravenna
- Dal 1986 al 1994 Dirigente medico presso UO Medicina, Ospedale Santa Maria delle Croci Ravenna

ISTRUZIONE E FORMAZIONE

- 31/12/1991 Specializzazione in Ematologia Generale (clinica e Laboratorio), Università di Ferrara
- 24/07/1984 Specializzazione in Oncologia
- 09/09/1982 Abilitazione all'esercizio della professione, Ordine dei Medici di Forlì
- 23/12/1981 Laurea in Medicina e Chirurgia, Università degli Studi di Bologna, con votazione 110/110 e lode

ULTERIORI INFORMAZIONI

Partecipazione in più di 50 trials clinici nazionali ed internazionali come Principal Investigator e Sub-Investigator.

Pubblicazioni

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.

Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, **Molinari AL**, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G; Fondazione Italiana Linfomi. Lancet Oncol. 2014 Jun;15(7):730-7. doi: 10.1016/S1470-2045(14)70191-3. Epub 2014 May 13.

Early application of percutaneous vertebroplasty reduces pain without affecting peripheral blood stem cell (PBSC) collection and transplant in newly diagnosed multiple myeloma (MM) patients.

Tosi P, Sintini M, **Molinari AL**, Imola M, Ciotta G, Tomassetti S, Mianulli AM, Ratta M, Mangianti S, Merli A, Polli V. Eur J Cancer Care (Engl). 2014 Nov;23(6):773-8. doi: 10.1111/ecc.12158. Epub 2013 Dec 2.

Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure.

Tosi P, Gamberi B, Castagnari B, **Molinari AL**, Savini P, Ceccolini M, Tani M, Merli A, Imola M, Mianulli AM, Cellini C, Tomassetti S, Merli F, Fattori P, Zaccaria A. Mediterr J Hematol Infect Dis. 2013 Jun; 3;5(e2013037). doi:

10.4084/MJHID.2013.037. Print 2013.

CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma.

Zaja F, Tomadini V, Zaccaria A, Lenoci M, Battista M, **Molinari AL**, Fabbri A, Battista R, Cabras MG, Gallamini A, Fanin R. Leuk Lymphoma. 2006 Oct;47(10):2174-80.

Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.

Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, **Molinari AL**, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M. J Clin Oncol. 2004 Jul 1;22(13):2654-61. Epub 2004 May 24.

B-cell compartment as the selective target for the treatment of immune thrombocytopenias.

Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, **Molinari AL**, Baccarani M, Fanin R. Haematologica. 2003 May;88(5):538-46.

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.

Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti S, Meloni G, Rizzo M, **Molinari AL**, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona E, Pileri SA, Mandelli F, Tura S. J Clin Oncol. 2003 Apr 1;21(7):1255-62

Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.

Zinzani PL, Tani M, **Molinari AL**, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M. Haematologica. 2002 Aug;87(8):816-21

The lung as a target organ in patients with hematologic disorders.

Poletti V, Salvucci M, Zanchini R, **Molinari AL**, Zuffa E, Poletti G, Zaccaria A. Haematologica. 2000 Aug;85(8):855-64. Review.

Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma.

Zinzani PL, Baccini C, Zaccaria A, Visani G, Buzzi M, Morelli A, **Molinari AL**, Salvucci M, Bendandi M, Rubboli D, Gherlinzoni F, Zanchini R, Tura S. Eur J Haematol. 1996 Nov;57(5):335-40.

All-trans retinoic acid and in vitro cytokine production by acute promyelocytic leukemia cells.

Visani G, Tosi P, Ottaviani E, Zaccaria A, Baccini C, Manfroi S, Pastano R, Remiddi C, Morelli A, **Molinari AL**, Zanchini R, Tura S. Eur J Haematol. 1996 Oct;57(4):301-6.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U. Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.

Sacchi S, Marcheselli R, Bari A, Buda G, Molinari AL, Baldini L, Vallisa D, Cesaretti M, Musto P, Ronconi S, Specchia G, Silvestris F, Guardigni L, Ferrari A, Chiappella A, Carella AM, Santoro A, Di Raimondo F, Marcheselli L, Pozzi S. Haematologica. 2016 May;101(5):e196-9. doi: 10.3324/haematol.2015.139329. Epub 2016 Feb 8.

Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy.

Zinzani PL, Tani M, Alinari L, Molinari AL, Stefoni V, Visani G, Gentilini P, Guardigni L, Fina M, Baccarani M. Leuk Lymphoma. 2005 Oct;46(10):1449-54.

Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.

Zinzani PL, Pulsoni A, Gentilini P, Visani G, Perrotti A, Molinari AL, Guardigni L, Tani M, Villivà N, Stefoni V, Alinari L, Martelli M, Bonifazi F, Pileri S, Tura S, Baccarani M. Leuk Lymphoma. 2004 Sep;45(9):1815-9.

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS. Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.

Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network. Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15643. [Epub ahead of print] No abstract available.

Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II

multicenter study of the Fondazione Italiana Linfomi

Storti S, Spina M, Pesce EA, Salvi F, Merli M, Ruffini A, Cabras G, Chiappella A, Angelucci E, Fabbri A, Liberati AM, Tani M, Musuraca G, Molinari A, Petrilli MP, Palladino C, Ciancia R, Ferrario A, Gasbarrino C, Monaco F, Fraticelli V, De Vellis A, Merli F, Luminari S. Haematologica. 2018 Aug;103(8):1345-1350. doi: 10.3324/haematol.2017.186569. Epub 2018 May 10.

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi

Sacchi S, Marcheselli R, Bari A, Buda G, Molinari AL, Baldini L, Vallisa D, Cesaretti M, Musto P, Ronconi S, Specchia G, Silvestris F, Guardigni L, Ferrari A, Chiappella A, Carella AM, Santoro A, Di Raimondo F, Marcheselli L, Pozzi S. Haematologica. 2016 May;101(5):e196-9. doi: 10.3324/haematol.2015.139329. Epub 2016 Feb 8. No abstract available.

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.

Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G; Fondazione Italiana Linfomi. Lancet Oncol. 2014 Jun;15(7):730-7. doi: 10.1016/S1470-2045(14)70191-3. Epub 2014 May 13.

Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure

Tosi P, Gamberi B, Castagnari B, Molinari AL, Savini P, Ceccolini M, Tani M, Merli A, Imola M, Mianulli AM, Cellini C, Tomassetti S, Merli F, Fattori P, Zaccaria A. Mediterr J Hematol Infect Dis. 2013 Jun 3;5(1):e2013037. doi: 10.4084/MJHID.2013.037. Print 2013.

Update on the role of autologous hematopoietic stem cell transplantation in multiple myeloma.

Tosi P, Imola M, Mianulli AM, Tomassetti S, Merli A, Molinari A, Mangianti S, Ratta M, Isidori A, Visani G. Mediterr J Hematol Infect Dis. 2012;4(1):e2012069. doi: 10.4084/MJHID.2012.069. Epub 2012 Nov 5.

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Rimini 08/01/2020

Dott.ssa Anna Lia Molinari